Pecularities of patients with coronary arteries restenosis

     Abstract.

Aim. To study the characteristics of patients with coronary artery restenosis in a retrospective (identification of patients with restenosis) and prospective (serum biomarker analysis) study. Methods. During the 5 years from primary stenting implantation, of observation, patients with coronary stenosis were identified. In 181 patients (67 with coronary restenosis and 114 without), the clinical, demographic and serum biomarker profiles were investigated.

Results. The frequency of coronary restenosis was more common in men than women (82.1% and 69.3% consequently, p = 0.047). Propensity Score Matching was used to balance the groups by gender, and as a result, the restenosis group showed an increase in hereditary predisposition to cardiovascular disease (p=0.024), non-sinus rhythm (less common in restenosis, p=0.020), decrease in Apo A1 (p=0.048) and increase - ALT (p=0.023).

Conclusions. Coronary artery restenoses were characterized by male gender, sinus rhythm, hereditary predisposition, and an increase in ALT and a decrease in Apo A1.

1. Aoki J, Nakazawa G, Tanabe K et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv., 2007. 69:380–386. DOI: 10.1002/ccd.20950.

2. Aoki J, Tanabe K, Hoye A et al. Mechanisms of drug-eluting stent restenosis. Cardiovasc Intervention and Therapeutics, 2021. 36: 23-29. DOI:10.1007/s12928-020-00734-7

3. Kuntz R, Baim D. Defining coronary restenosis. Newer clinical and angiographic paradigms. Circulation, 1993. 88 (3): 1310–1323 DOI:/10.1161/01.CIR.88.3.1310

4. Enikeeva AM, Gazizova LYu, Gareeva DF, Rakhimova RF, Amineva AM, Buzaev IV, Zagidullin NSh. Predictors of coronary in-stent restenosis. Bulletin of clinical medicine. 2023; 6(4): 83-89 (in Russ.) DOI: 10.20969/VSKM.2023.16(4).83-89

5. Mingrui Li, Jingyuan Hou, Xiaodong Gu, Ruiqiang Weng, Zhixiong Zhong and Sudong Liu Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China European Journal of Medical Research https://doi.org/10.1186/s40001-022-00640-z .

6. Omar A, et al. Review: stent fracture in the drug-eluting stent era. Cardio- vasc Revasc Med. 2016;17(6):404–11.

7. Buccheri D, et al. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis. 2016;8(10):E1150–62.

8. Mazaev V.P., Komkov A.A., Ryazanova S.V. Clinical condition and cardiovascular risk factors displaying neoatherosclerosis in stented coronary arteries with developing restenosis. Cardiovascular Therapy and Prevention. 2016;15(5):64-69. (In Russ.) https://doi.org/10.15829/1728-8800-2016-5-64-69

9. Shlofmitz E, Case BC, Chen Y et al. In-Stent Restenosis Classification: A Mechanism-Based Approach to the Treatment of Restenosis. Cardiovasc Revasc Med. 2021. Dec;33: 62-67. DOI: 10.1016/j.carrev.2021.06.004

10. Enikeeva AM, Gazizova LY, Buzaev IV, et al. Prediction of in-stent restenosis based on systematic and retrospective analyses. Global Transl Med. 2024:3(4):4957.doi: 10.36922/gtm.4957

11. Nayor M, Brown KJ, Vasan RS. The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk. Circ Res. 2021 Jan 22;128(2):287-303. doi: 10.1161/CIRCRESAHA.120.315890.

12. Wang Z, Sheng L, Gu H, Yang F, Xie H, Li M. Rivaroxaban and Aspirin in Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis: A Retrospective Cohort Study. Ann Vasc Surg. 2024 Nov;108:338-345. doi: 10.1016/j.avsg.2024.05.031. Epub 2024 Jul 14. PMID: 39013487.

13. Wang X, Zhang M, Cheng J, Zhou H. Association of serum apoA-I with in-stent restenosis in coronary heart disease. BMC Cardiovasc Disord. 2022 Aug 4;22(1):355. doi: 10.1186/s12872-022-02762-y. PMID: 35927634; PMCID: PMC9354313

14. Cochran BJ, Ong KL, Manandhar B, Rye KA. APOA1: a Protein with Multiple Therapeutic Functions. Curr Atheroscler Rep. 2021 Feb 16;23(3):11. doi: 10.1007/s11883-021-00906-7

15. Jamalinia M, Zare F, Noorizadeh K, Bagheri Lankarani K. Systematic review with meta-analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024 Feb;59(4):445-458. doi: 10.1111/apt.17869